US 2025/0144205 A1 · COMPOSITIONS AND METHODS FOR TREATING INFECTIOUS DISEASES

Abstract

Compositions, methods, and processes for making and using polypeptides, peptides and antibodies for treating a subject in need of therapy for pathogen-induced infection and non-pathogen-induced (organ fibrosis, COPD and asthma), symptom, disease, disorder, injury, or condition, containing a) multiple EGF-like-domains-9 (MEGF9) or a biologically active fragment thereof; b) uncoordinated receptor 5A (UNC5A) or a biologically active fragment thereof; c) dolichyl-phosphate beta-glucosyltransferase (ALG5) or a biologically active fragment thereof; d) a combination of two or three of a)-c); e) an antibody specific for a); f) an antibody specific for b); g) an antibody specific for c); h) a combination of two or three of e)-g); or i) a combination of at least one of a)-c) and at least one of e)-g).

Claims55

Dependent claims

A method of treating a subject in need of therapy for a pathogen-induced infection, symptom, disease, disorder, injury, or condition, comprising administering to the subject:

a) multiple EGF-like-domains-9 (MEGF9) or a biologically active fragment thereof;
b) uncoordinated receptor 5 A (UNC5A) or a biologically active fragment thereof;
c) dolichyl-phosphate beta-glucosyltransferase (ALG5) or a biologically active fragment thereof;
d) a combination of two or three of a)-c);
e) an antibody specific for a);
f) an antibody specific for b);
g) an antibody specific for c);
h) a combination of two or three of e)-g);
or
i) a combination of at least one of a)-c) and at least one of e)-g).

7 more elements

An M9-binding protein comprising:

a heavy chain variable region comprising
a variable heavy chain complementarity determining region 1 (VH CDR1) comprising SEQ ID NO:
108,
a variable heavy chain complementarity determining region 2 (VH CDR2) comprising SEQ ID NO:
109, and
a variable heavy chain complementarity determining region 3(VH CDR3) comprising SEQ ID NO:
110;
and
a light chain variable region comprising
a variable light chain complementarity determining region 1 (VL CDR1) comprising SEQ ID NO:
115,
a variable light chain complementarity determining region 2 (VL CDR2) comprising SEQ ID NO:
116, and
a variable light chain complementarity determining region 3 (VL CDR3) comprising a SEQ ID NO:
1 I7;
or
a heavy chain variable region comprising
a VH CDR1 comprising SEQ ID NO:
122,
a VH CDR2 comprising SEQ ID NO:
123, and
a VH CDR3 comprising SEQ ID NO:
212 and
a light chain variable region comprising
a VL CDR1 comprising SEQ ID NO:
129,
a VL CDR2 comprising SEQ ID NO:
130, and
a VL CDR3 comprising a SEQ ID NO:
131;
or
a heavy chain variable region comprising
a VH CDR1 comprising SEQ ID NO:
136,
a VH CDR2 comprising SEQ ID NO:
137, and
a VH CDR3 comprising SEQ ID NO:
138;
and
a light chain variable region comprising
a VL CDR1 comprising SEQ ID NO:
143,
a VL CDR2 comprising SEQ ID NO:
144, and
a VL CDR3 comprising a SEQ ID NO:
145;
or
a heavy chain variable region comprising
a VH CDR1 comprising SEQ ID NO:
150,
a VH CDR2 comprising SEQ ID NO:
151, and
a VH CDR3 comprising SEQ ID NO:
152;
and
a light chain variable region comprising
a VL CDR1 comprising SEQ ID NO:157,
a VL CDR2 comprising SEQ ID NO:
158, and
a VL CDR3 comprising a SEQ ID NO:
159;
or
a heavy chain variable region comprising
a VL CDR1 comprising SEQ ID NO:
164,
a VH CDR2 comprising SEQ ID NO:
165, and
a VH CDR3 comprising SEQ ID NO:
166;
and
a light chain variable region comprising
a VL CDR1 comprising SEQ ID NO:
171,
a VL CDR2 comprising SEQ ID NO:
172, and
a VL CDR3 comprising SEQ ID NO:
173;
or
a heavy chain variable region comprising
a VH CDR1 comprising SEQ ID NO:
178,
a VH CDR2 comprising SEQ ID NO:
179, and
a CDR3 comprising SEQ ID NO:
180 and
a light chain variable region comprising
a VL CDR1 comprising SEQ ID NO:
185,
a VL CDR2 comprising SEQ ID NO:
186, and
a VL CDR3 comprising SEQ ID NO:
187.

89 more elements

Dependencies are inferred from the claim text.

Compositions and methods for treating infectious diseases

Life of this patent

Compositions and methods for treating infectious diseases

Life of this patent

Abstract

Claims55